Summary
33.20 -1.47(-4.24%)11/01/2024
Castle Biosciences Inc (CSTL)
Castle Biosciences Inc (CSTL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.24 | 9.12 | 23.79 | 43.97 | 57.34 | 122.22 | 47.45 | 62.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 33.20 | |
| Open | 35.06 | |
| High | 35.39 | |
| Low | 32.58 | |
| Volume | 732,494 | |
| Change | -1.47 | |
| Change % | -4.24 | |
| Avg Volume (20 Days) | 351,333 | |
| Volume/Avg Volume (20 Days) Ratio | 2.08 | |
| 52 Week Range | 14.22 - 34.73 | |
| Price vs 52 Week High | -4.41% | |
| Price vs 52 Week Low | 133.47% | |
| Range | 0.67 | |
| Gap Up/Down | -0.07 | |
Fundamentals | ||
| Market Capitalization (Mln) | 777 | |
| EBIDTA | 5,935,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 87.50 | |
| Book Value | 16.2820 | |
| Earnings Per Share | -1.2390 | |
| EPS Estimate Current Quarter | -0.4000 | |
| EPS Estimate Next Quarter | -0.3900 | |
| EPS Estimate Current Year | -1.4700 | |
| EPS Estimate Next Year | -1.4500 | |
| Diluted EPS (TTM) | -1.2390 | |
| Revenues | ||
| Profit Marging | -0.3446 | |
| Operating Marging (TTM) | -0.3454 | |
| Return on asset (TTM) | -0.0579 | |
| Return on equity (TTM) | -0.1029 | |
| Revenue TTM | 86,345,000 | |
| Revenue per share TTM | 3.5950 | |
| Quarterly Revenue Growth (YOY) | 0.5430 | |
| Quarterly Earnings Growth (YOY) | -0.9260 | |
| Gross Profit (TTM) | 52,964,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.4900 | |
| Revenue Enterprise Value | 10.0130 | |
| EBITDA Enterprise Value | 11,562.5745 | |
| Shares | ||
| Shares Outstanding | 25,300,300 | |
| Shares Float | 23,763,094 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 9.39 | |
| Institutions (%) | 88.08 | |
11/01 10:16 EST - zacks.com
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
10/29 16:30 EST - businesswire.com
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esophagus.
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esophagus.
10/28 07:00 EST - businesswire.com
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces that its executive management is scheduled to present a company overview at three investor conferences in November.
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces that its executive management is scheduled to present a company overview at three investor conferences in November.
10/23 09:51 EST - zacks.com
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
10/22 13:06 EST - zacks.com
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
10/20 05:00 EST - businesswire.com
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle will share new data at ASDS supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests.
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle will share new data at ASDS supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests.
10/16 07:00 EST - businesswire.com
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of two recent studies that provide further support for the clinical need of its MyPath® Melanoma GEP test.
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of two recent studies that provide further support for the clinical need of its MyPath® Melanoma GEP test.
10/15 10:22 EST - zacks.com
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
10/15 05:51 EST - zacks.com
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?
Castle Biosciences (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?
Castle Biosciences (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
10/14 07:00 EST - businesswire.com
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024.
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024.
10/11 07:00 EST - businesswire.com
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the OHSU Dept of Dermatology, being held Oct. 17-21, 2024.
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the OHSU Dept of Dermatology, being held Oct. 17-21, 2024.
10/09 07:00 EST - businesswire.com
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences' DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #2024SMRCongress--Castle will present new data on DecisionDx-Melanoma and DecisionDx-UM at the 21st International Congress of the Society for Melanoma Research (SMR).
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences' DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #2024SMRCongress--Castle will present new data on DecisionDx-Melanoma and DecisionDx-UM at the 21st International Congress of the Society for Melanoma Research (SMR).
10/07 13:05 EST - zacks.com
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
10/02 07:00 EST - businesswire.com
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--The company will hold a groundbreaking ceremony Oct. 22 to celebrate the recent construction start of its new corporate campus and office building.
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--The company will hold a groundbreaking ceremony Oct. 22 to celebrate the recent construction start of its new corporate campus and office building.
09/27 17:15 EST - businesswire.com
New Data at ASTRO 2024 Shows Castle Biosciences' DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO--Castle will share data at ASTRO24 showing its DecisionDx-SCC test can provide impactful risk stratification in high-risk SCC patient sub-populations.
New Data at ASTRO 2024 Shows Castle Biosciences' DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO--Castle will share data at ASTRO24 showing its DecisionDx-SCC test can provide impactful risk stratification in high-risk SCC patient sub-populations.
08/16 06:41 EST - seekingalpha.com
Castle Biosciences: Inflection Into Profitability
Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. CSTL faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field.
Castle Biosciences: Inflection Into Profitability
Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. CSTL faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field.
08/05 22:35 EST - seekingalpha.com
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Sung Nam - Scotiabank Subbu Nambi - Guggenheim Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences Second Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Sung Nam - Scotiabank Subbu Nambi - Guggenheim Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences Second Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
08/05 18:46 EST - zacks.com
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.70 per share a year ago.
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.70 per share a year ago.
08/05 16:05 EST - businesswire.com
Castle Biosciences Reports Second Quarter 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2024.
Castle Biosciences Reports Second Quarter 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2024.
07/29 11:06 EST - zacks.com
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.